Log In
BCIQ
Print this Print this
 

Melacine (Melacine melanoma theraccine)

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionVaccine consisting of lysed cells from 2 melanoma cell lines combined with Detox adjuvant containing monophosphoryl lipid A (MPL) and mycobacterial cell wall
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentMarketed
Standard IndicationMelanoma
Indication DetailsPrevent recurrence in stage II melanoma after primary tumors have been surgically removed; Treat late stage melanoma; Treat malignant stage IV melanoma; Treat melanoma; Treat stage IV, disseminated melanoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today